Visceral leishmaniasis: Elimination with existing interventions

The Lancet Infectious Diseases

Volumn 11, Issue 4, 2011, Pages 322-325

  Matlashewski, Greg ^a,b   Arana, Byron ^a   Kroeger, Axel ^a   Battacharya, Sujit ^a,c   Sundar, Shyam ^d   Das, Pradeep ^e   Sinha, Prabhat Kumar ^e   Rijal, Suman ^f   Mondal, Dinesh ^g   Zilberstein, Dan ^b,h   Alvar, Jorge ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

^c WHO   (India)

^d BANARAS HINDU UNIVERSITY   (India)

^e Rajendra Medical Research Institute   (India)

^f B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^g INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^h TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; PAROMOMYCIN;

ENDEMIC DISEASE; INDIA; INFECTION CONTROL; NOTE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT INDICATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIASIS, VISCERAL; PAROMOMYCIN; PHOSPHORYLCHOLINE;

EID: 79953031840     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70320-0     Document Type: Note

References (27)

1. Bern C, Maguire H, Alvar J Complexities of assessing the disease burden attributed to leishmaniasis. PLoS Negl Trop Dis 2008, 2:e313.
2. Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, Breman JG Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis 2004, 38:871-878.
3. Alvar J, Yactayo S, Bern C Leishmaniasis and poverty. Trends Parasitol 2006, 22:552-557.
4. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 2007, 5:873-882.
5. Desjeux P Leishmaniasis: current situation and new perspectives. Comp Immunol Microb Infect Dis 2004, 27:305-318.
6. Murray HW, Berman JD, Davies CR, Saravia NG Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
7. Bern C, Courtenal O, Alvar J Of cattle, sandflies and men: a systematic review of the risk factor analyses for south asia visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis 2010, 4:e599.
8. Den Boer M, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009, 14:395-410.
9. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray H Single-dose Liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010, 362:504-512.
10. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ 2001, 323:419-422.
11. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003, 37:800-804.
12. Thakur CP A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001, 17:67-70.
13. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002, 66:143-146.
14. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004, 38:377-383.
15. Report of a meeting of the WHO Expert Committee on the Control of the Leishmaniases 2010, WHO: Control of the Leishmaniases, World Health Organization, Geneva.
16. Hirve S, Singh P, Kumar K, et al. Effectiveness, costs and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh and Nepal. Am J Trop Med Hyg 2010, 83:507-511.
17. Goad L, Holz G, Beach D Sterols of Leishmania species: implications for biosynthesis. Mol Biochem Parasitol 1984, 10:161-170.
18. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 2009, 48:e16-e22.
19. Perea S, Patterson T Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002, 35:1073-1080.
20. Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010, 10:184-194.
21. Sundar S, Sinha PK, Verma D, et al. Ambisome (one day) plus miltefosine (14 days) for Indian Kala-azar. Trans R Soc Trop Med Hyg 2011, 105:115-117.
22. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011, 377:477-486.
23. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana M, Davidson R Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007, 101:19-24.
24. Olliaro P, Sundar S Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009, 14:88-92.
25. Mondal D, Singh S, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: Reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009, 3:e355.
26. Sharma U, Singh S Insect vectors of Leishmaniasis: distribution, physiology and their control. J Vector Borne Dis 2008, 45:255-272.
27. Alexander B, Maroli M Control of phlebotomine sandflies. Med Vet Entomol 2003, 17:1-18.